Form 4: Aadi Bioscience Director Acquires Stock Options

Anupam Dalal, a director of Aadi Bioscience, acquired stock options for 45,832 shares on June 12, 2024.

Summary

• On June 12, 2024, Anupam Dalal, a director of Aadi Bioscience, Inc., acquired stock options for 45,832 shares of common stock.
• The exercise price of these options is $1.70.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a standard compensation practice. The director's acquisition of options suggests a positive outlook, but it's not overwhelmingly significant.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service, aligning their interests with the company's long-term success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.
• The vesting schedule of one year is fairly standard, although some companies may use longer or shorter vesting periods.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's performance.

Key Dates